![](https://endpts.com/wp-content/uploads/2019/03/lieping-chen-endpts-tile-vj-oncology.jpg)
Backed with $180M-plus in cash, I/O trailblazer Lieping Chen spotlights NextCure's preclinical work on next-gen antibody
Right on the heels of nailing a $40 million upfront for its oncology R&D collaboration deal with Eli Lilly and bringing its tally of cash raised to $180 million with an ambitious venture round, Yale spinout NextCure has laid the scientific foundation for the immuno-oncology company in a new preclinical study just published in Nature Medicine.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.